Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.
Teng LiShouzheng WangJianming YingYan WangXing-Sheng HuXuezhi HaoZiyi XuPuyuan XingJun-Ling LiPublished in: Thoracic cancer (2021)
Our findings suggested that afatinib is effective in patients with uncommon mutations. Mechanisms of afatinib resistance vary and need further investigation.